M&A: Page 2

Teleflex lines up $525M to buy hemostat specialist Z-Medica

The medtech predicts the trauma surgery and emergency medicine-focused products will begin adding up to $70 million in revenue next year, providing growth drivers outside its key interventional urology segment.

By Maria Rachal • Oct. 29, 2020

Smith & Nephew lays path to 10% growth for acquired Integra assets

The medtech is moving deeper into the extremity orthopaedics turf fought over by the likes of Zimmer Biomet and Stryker acquisition target Wright Medical.

By Nick Paul Taylor • Oct. 29, 2020

Exact Sciences stock jumps on cancer detection deals for Thrive, Base Genomics

The cancer diagnostics company is aiming to bolster its technology pipeline weeks after Illumina put up $8 billion to acquire liquid biopsy developer Grail.

By Nick Paul Taylor , Maria Rachal • UPDATED: Oct. 27, 2020 at 12:12 p.m.

Stryker buyout of Wright poised to pass 1-year mark without closing

CEO Kevin Lobo said last month the $5.4 billion buyout, which has faced antitrust hurdles, was on track to be finalized in early October.  

By Maria Rachal • Oct. 26, 2020

Steris inks $850M deal for Key Surgical adds to medtech M&A wave

CEO Walter Rosebrough gave a nod to current low interest rates but said Steris had been looking at this potential transaction "for years, not months."

By Susan Kelly • Oct. 07, 2020

Analysts predict Zimmer Biomet M&A in 2021 to speed growth

The medtech is likely to initially target private orthopaedic companies worth up to $300 million, Needham analysts specified. The spine and dental businesses, meanwhile, could be on the chopping block.

By Nick Paul Taylor • Oct. 07, 2020

M&A on horizon as deep-pocketed medtechs eye distressed assets: EY

The combination of smaller companies questioning their pandemic survival and larger companies with considerable capital may spark a buying surge, the consultancy said in its annual medtech report.

By Nick Paul Taylor • Oct. 06, 2020

Medtronic to expand dialysis access position with Avenu Medical buyout

The deal is the second tuck-in acquisition this year for the medtech's peripheral vascular business and the company's sixth overall, following additions to insulin delivery, surgery and spinal cord stimulation offerings.

By Maria Rachal • UPDATED: Sept. 30, 2020 at 2:29 p.m.

COVID-19 spurred a medtech M&A boom this summer. Will it last?

Siemens Healthineers' CEO was rebuffed by his counterpart at Varian in January. But come May, the impact of coronavirus began to become clear. 

By Nick Paul Taylor • Sept. 30, 2020

Smith & Nephew inks $240M deal to buy orthopaedic assets from Integra

The U.K.-based medtech will gain control of a portfolio of shoulder replacement products and other devices that generated revenues of $90 million last year.

By Nick Paul Taylor • Sept. 29, 2020

Illumina inks $8B Grail buyout for liquid biopsy market. Investors are not sold.

Shares in Illumina, which formed cancer detection startup Grail in 2016, fell as analysts questioned whether the cash-and-stock deal plays to its strengths.

By Nick Paul Taylor , Greg Slabodkin • Sept. 21, 2020

Qiagen completes takeover of PCR automation player NeuMoDx for $248M

The still-independent Dutch molecular diagnostics company said NeuMoDx devices process test results three times as fast as some rival systems.

By Nick Paul Taylor • Sept. 18, 2020

Intersect ENT strikes €60 Fiagon buyout to expand in balloon sinuplasty

The takeover of the German electromagnetic surgical navigation specialist comes two months after a report that Medtronic moved to acquire Intersect.

By Nick Paul Taylor • Sept. 16, 2020

Stryker reaches agreement with Colfax for Wright Medical deal divestitures

The medtech disclosed Thursday the orthopaedics competitor's DJO Global subsidiary agreed to acquire its ankle and finger joint replacement businesses to shore up U.S. and U.K. antitrust concerns.

By Maria Rachal • UPDATED: Oct. 16, 2020 at 11:47 a.m.

Stryker stretches Wright Medical share offer into Q4

As the medtech makes the fifth offer extension since the $4 billion acquisition was announced last November, the company is approaching the latest time it said the deal would close.

By Susan Kelly • UPDATED: Sept. 29, 2020 at 11:32 a.m.

Philips pens $275M Intact Vascular deal to acquire implant

The buy adds the first FDA-approved vascular implant for below-the-knee interventions to the Dutch conglomerate's portfolio.

By Nick Paul Taylor • Aug. 28, 2020

Hologic inks $80M Acessa buyout to expand women's health business

The cash acquisition, plus contingent payments based on future revenue growth, will add a treatment for benign uterine fibroid to the medtech's portfolio.

By Nick Paul Taylor • Aug. 26, 2020

IDx rebrands, buys 3Derm to expand automated AI portfolio

The takeover gives the company, now known as Digital Diagnostics, control of two breakthrough device-designated autonomous artificial intelligence systems.

By Nick Paul Taylor • Aug. 20, 2020

Medtronic seeks leg up in lagging pen market with Companion Medical buy

As Dexcom and Abbott grow share in the continuous glucose monitoring market and Insulet and Tandem forge on with interoperable insulin pump systems, Medtronic is hoping to jump ahead with a connected pen.

By Maria Rachal • Aug. 17, 2020

Thermo Fisher-Qiagen deal falls apart after failing to secure shareholder support

Thermo Fisher recently raised its bid for Qiagen shares, taking into account the company's COVID-19 testing gains. But when the offer expired Monday, less than half of shares were tendered.

By Nick Paul Taylor , Maria Rachal , Greg Slabodkin • UPDATED: Aug. 13, 2020 at 11:39 a.m.

Livongo scooped up by Teladoc in $18.5B deal

An explosion in the use of virtual care during the pandemic may have sped up the timeline for the merger. Both companies' share prices are down on the news.

By Shannon Muchmore • UPDATED: Aug. 5, 2020 at 11:10 a.m.

Americas drag on Qiagen as Thermo Fisher deal goes down to the wire

A hedge fund that owns 8% of Qiagen "fully" expects the Thermo Fisher offer to fail, calling it “wholly inadequate.”

By Nick Paul Taylor • Aug. 05, 2020

Varian sold to Siemens Healthineers in $16.4B all-cash deal

Breaking with a trend of smaller medtech deal values in 2020, the pact will see radiation oncology equipment and software maker Varian Medical Systems operate as an independent company under Siemens Healthineers.

By Maria Rachal • UPDATED: Aug. 3, 2020 at 9:54 a.m.

Coronavirus could fuel clinical lab M&A by stressing smaller hospital players

Consultancy Kaufman Hall predicts a ramp-up of deals throughout the year, as hospital-owned labs seek support amid the pandemic. That forecast meshes with comments from Quest's CEO last week.

By Nick Paul Taylor • July 29, 2020

Medical device deal values down 88% amid COVID-19 disruption: PwC

Going forward, M&A may rise in light of recent deferral of elective procedures, which analysts say “could create the need for significant consolidation as companies work to remain competitive.”  

By Nick Paul Taylor • July 23, 2020